Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free LONA Stock Alerts

Athira Pharma (LONA) Competitors

Athira Pharma logo
$7.39 +0.15 (+2.07%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$7.40 +0.00 (+0.07%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

LONA vs. TKNO, EDIT, INDP, IMRX, and MGNX

Should you buy Athira Pharma stock or one of its competitors? MarketBeat compares Athira Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Athira Pharma include Alpha Teknova (TKNO), Editas Medicine (EDIT), Indaptus Therapeutics (INDP), Immuneering (IMRX), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical products" industry.

How does Athira Pharma compare to Alpha Teknova?

Alpha Teknova (NASDAQ:TKNO) and Athira Pharma (NASDAQ:LONA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Athira Pharma has a net margin of 0.00% compared to Alpha Teknova's net margin of -41.07%. Alpha Teknova's return on equity of -24.32% beat Athira Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Alpha Teknova-41.07% -24.32% -16.34%
Athira Pharma N/A -381.01%-225.74%

Alpha Teknova has higher revenue and earnings than Athira Pharma. Alpha Teknova is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alpha Teknova$41.80M6.37-$17.26M-$0.32N/A
Athira PharmaN/AN/A-$105.61M-$5.21N/A

Alpha Teknova has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.01, meaning that its stock price is 101% more volatile than the broader market.

Athira Pharma has a consensus price target of $15.00, indicating a potential upside of 102.98%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Athira Pharma is more favorable than Alpha Teknova.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alpha Teknova
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Athira Pharma
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

In the previous week, Alpha Teknova had 2 more articles in the media than Athira Pharma. MarketBeat recorded 3 mentions for Alpha Teknova and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 1.89 beat Alpha Teknova's score of 1.20 indicating that Athira Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Alpha Teknova Positive
Athira Pharma Very Positive

13.8% of Alpha Teknova shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 13.2% of Alpha Teknova shares are owned by insiders. Comparatively, 25.7% of Athira Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Athira Pharma beats Alpha Teknova on 9 of the 15 factors compared between the two stocks.

How does Athira Pharma compare to Editas Medicine?

Athira Pharma (NASDAQ:LONA) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

Athira Pharma has higher earnings, but lower revenue than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Athira PharmaN/AN/A-$105.61M-$5.21N/A
Editas Medicine$40.52M6.28-$160.06M-$1.23N/A

Athira Pharma has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. Athira Pharma's return on equity of -381.01% beat Editas Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Athira PharmaN/A -381.01% -225.74%
Editas Medicine -281.59%-677.39%-58.25%

Athira Pharma has a beta of 2.01, meaning that its share price is 101% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.1, meaning that its share price is 110% more volatile than the broader market.

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Athira Pharma presently has a consensus target price of $15.00, indicating a potential upside of 102.98%. Editas Medicine has a consensus target price of $5.40, indicating a potential upside of 107.69%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Editas Medicine is more favorable than Athira Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Athira Pharma
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Editas Medicine
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

In the previous week, Editas Medicine had 2 more articles in the media than Athira Pharma. MarketBeat recorded 3 mentions for Editas Medicine and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 1.89 beat Editas Medicine's score of 1.09 indicating that Athira Pharma is being referred to more favorably in the media.

Company Overall Sentiment
Athira Pharma Very Positive
Editas Medicine Positive

Summary

Editas Medicine beats Athira Pharma on 9 of the 15 factors compared between the two stocks.

How does Athira Pharma compare to Indaptus Therapeutics?

Athira Pharma (NASDAQ:LONA) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 25.7% of Athira Pharma shares are held by company insiders. Comparatively, 9.9% of Indaptus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Athira Pharma's return on equity of -381.01% beat Indaptus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Athira PharmaN/A -381.01% -225.74%
Indaptus Therapeutics N/A -1,030.07%-299.69%

Athira Pharma has a beta of 2.01, meaning that its share price is 101% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Athira Pharma presently has a consensus price target of $15.00, indicating a potential upside of 102.98%. Given Athira Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Athira Pharma is more favorable than Indaptus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Athira Pharma
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Indaptus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Athira Pharma is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Athira PharmaN/AN/A-$105.61M-$5.21N/A
Indaptus TherapeuticsN/AN/A-$20.85M-$15.40N/A

In the previous week, Indaptus Therapeutics had 1 more articles in the media than Athira Pharma. MarketBeat recorded 2 mentions for Indaptus Therapeutics and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 1.89 beat Indaptus Therapeutics' score of 0.44 indicating that Athira Pharma is being referred to more favorably in the media.

Company Overall Sentiment
Athira Pharma Very Positive
Indaptus Therapeutics Neutral

Summary

Athira Pharma beats Indaptus Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Athira Pharma compare to Immuneering?

Immuneering (NASDAQ:IMRX) and Athira Pharma (NASDAQ:LONA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Immuneering currently has a consensus price target of $17.57, indicating a potential upside of 306.75%. Athira Pharma has a consensus price target of $15.00, indicating a potential upside of 102.98%. Given Immuneering's stronger consensus rating and higher probable upside, analysts clearly believe Immuneering is more favorable than Athira Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immuneering
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Athira Pharma
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

In the previous week, Immuneering had 4 more articles in the media than Athira Pharma. MarketBeat recorded 5 mentions for Immuneering and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 1.89 beat Immuneering's score of 0.70 indicating that Athira Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Immuneering Positive
Athira Pharma Very Positive

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 22.9% of Immuneering shares are owned by insiders. Comparatively, 25.7% of Athira Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Immuneering is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmuneeringN/AN/A-$56.03M-$1.17N/A
Athira PharmaN/AN/A-$105.61M-$5.21N/A

Immuneering has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.01, suggesting that its stock price is 101% more volatile than the broader market.

Immuneering's return on equity of -31.93% beat Athira Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuneeringN/A -31.93% -29.92%
Athira Pharma N/A -381.01%-225.74%

Summary

Immuneering beats Athira Pharma on 10 of the 14 factors compared between the two stocks.

How does Athira Pharma compare to MacroGenics?

MacroGenics (NASDAQ:MGNX) and Athira Pharma (NASDAQ:LONA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

MacroGenics presently has a consensus target price of $5.50, suggesting a potential upside of 48.65%. Athira Pharma has a consensus target price of $15.00, suggesting a potential upside of 102.98%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Athira Pharma is more favorable than MacroGenics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MacroGenics
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29
Athira Pharma
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

96.9% of MacroGenics shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 13.6% of MacroGenics shares are held by company insiders. Comparatively, 25.7% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MacroGenics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.01, meaning that its stock price is 101% more volatile than the broader market.

Athira Pharma has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. MacroGenics' return on equity of -147.80% beat Athira Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
MacroGenics-44.79% -147.80% -28.40%
Athira Pharma N/A -381.01%-225.74%

MacroGenics has higher revenue and earnings than Athira Pharma. MacroGenics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MacroGenics$157.08M1.50-$74.62M-$1.10N/A
Athira PharmaN/AN/A-$105.61M-$5.21N/A

In the previous week, MacroGenics had 4 more articles in the media than Athira Pharma. MarketBeat recorded 5 mentions for MacroGenics and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 1.89 beat MacroGenics' score of 0.62 indicating that Athira Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
MacroGenics Positive
Athira Pharma Very Positive

Summary

MacroGenics and Athira Pharma tied by winning 7 of the 14 factors compared between the two stocks.

Get Athira Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for LONA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LONA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LONA vs. The Competition

Export
MetricAthira PharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$69.42M$3.67B$6.87B$12.26B
Dividend YieldN/A2.19%2.67%9.79%
P/E Ratio-1.4221.4827.1423.64
Price / SalesN/A170.08517.0889.45
Price / CashN/A157.9050.5459.64
Price / Book2.487.8810.286.07
Net Income-$105.61M$23.86M$3.60B$331.99M
7 Day Performance2.35%-3.82%-1.27%-0.63%
1 Month Performance-14.96%-2.61%-0.37%-2.00%
1 Year PerformanceN/A32.79%18.30%13.62%

Athira Pharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LONA
Athira Pharma
3.5525 of 5 stars		$7.39
+2.1%		$15.00
+103.0%		N/A$69.42MN/AN/A40
TKNO
Alpha Teknova
0.577 of 5 stars		$5.34
+0.8%		N/A-3.9%$284.15M$40.52MN/A240
EDIT
Editas Medicine
3.0825 of 5 stars		$2.89
+0.3%		$5.40
+86.9%		-20.2%$281.97M$40.52MN/A230
INDP
Indaptus Therapeutics
0.3956 of 5 stars		$2.52
+2.4%		N/A-73.6%$278.58MN/AN/A6
IMRX
Immuneering
2.9198 of 5 stars		$4.46
+4.0%		$17.57
+294.0%		+8.0%$277.55MN/AN/A60

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:LONA) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel